Jagsonpal Pharmaceuticals
BSE 507789
3 stories, newest first.
- Jagsonpal Pharmaceuticals sets Q2/H1 FY27 earnings conference call for October 29, 2026, hosted by Go India Advisors
- Board meeting on 28 October 2026 to consider and approve unaudited results for September quarter
- Jagsonpal completes acquisition of Group Pharmaceuticals' wellness portfolio; ~₹23.7 Cr upfront plus up to ~₹23.0 Cr deferred
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.